The Italian drama continued on Tuesday, yet it may not have negatively weigh on investors, leaving the S&P 500 unchanged. The Dow Jones Industrial Average outperformed, climbing 0.5% to a new all-time high, while the Nasdaq Composite lagged for the second day in a row, closing 0.5% lower. The Russell 2000 continued to struggle on Tuesday, closing 1.0% lower, thus extending the weekly loss to -2.4%.
Today we dig deeper into the recent sell-off seen in Teva Pharmaceutical (TEVA).Read More
On June 21, 2018, the Government of Canada announced that Bill C-45 received Royal Assent and that it will come into force on October 17, 2018. Management has invested significant effort in securing channels into the future regulated recreational markets. This, in addition to various states in the US beginning to work towards legalization of cannabis, has resulted in growing interest from investors. This effect can be magnified if Congress passes the 2018 Farm Bill which will fully legalize commercial hemp production in the US. Various other countries have also worked to remove various government red tape surrounding cannabis.
Marijuana or cannabis is one of the most popular recreational drugs used worldwide. It has been estimated that more than 175 million people between the age of 15 to 64 have used the drug at least once. Medical cannabis, refers to use of the plant’s cannabinoids as medical therapy to treat disease or alleviate symptoms. Cannabinoids can be administered orally, inhaled, smoked, mixed with food, or made into tea. They active compound, cannabinoids, can be taken in the herbal form, extracted naturally or synthetically created in a lab.
In this post we dissect three of our favourite cannabis stocks to own in 2018.Read More
The Federal Reserve increased short-term interest rates on Wednesday, as expected, raising the fed funds target range by 25 basis points to 2.00-2.25%.
Stocks were up modestly ahead of the release of the Fed’s decision, which crossed the wires at 2:00 PM ET, and extended gains after the central bank removed the word ‘accomodative’ from its policy statement. However, that initial move was reversed, and then some, following a post-decision press conference from Fed Chairman Jerome Powell, during which he said the language change didn’t signal a change in the Fed’s path for rate hikes.
The S&P 500 was up as much as 0.5% on Wednesday, but fell sharply in the final minutes of the session to finish with a loss of 0.3%. The tech-heavy Nasdaq Composite ended lower by 0.2%, the blue-chip Dow Jones Industrial Average finished lower by 0.4%, and the small-cap Russell 2000 lost 1.0%.Read More
Stocks had a interesting day on Friday, with the underperformance of financial and technology sectors balancing gains in other sectors. The Dow Jones Industrial Average finished the day up 0.3%, once again closing at a new all-time high for the second day in a row. The S&P 500 finished essentially flat, and the tech-heavy Nasdaq closed down 0.5%. For the week, the S&P 500 and the Dow added 0.9% and 2.3%, respectively, while the Nasdaq lost 0.3%. Today we looked at the big Pharma BioMarin Pharmaceutical, Inc. (BMRN) and whether it is a good time to buy now, and what to expect in the coming months.Read More
Stocks and Securities Even though, trade war continues to weigh on investors minds stocks continued to rally Thursday. The Dow Jones Industrial…Read More
Viking Therapeutics (VKTX) set the biotech sector on fire on September 18th being up as much as 160% only to close the day more than 80% up from the previous days close.Viking Therapeutics (VKTX) has come a long way in just less than a year. We have to remind our readers that the stock is up 1550% YTD and just about the same since it landed on our watchlist last year. Needless to say, we recommended on multiple occasions to our premium members to use any weakness to accumulate shares of Viking Therapeutics (VKTX). Congrats to our readers. Now let us dig a bit deeper into the recent news and what to expect in the coming months.Read More